Origin Therapeutics Holdings (XCNQ:ORIG) Net Current Asset Value : C$0.05 (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Origin Therapeutics Holdings Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Origin Therapeutics Holdings's net current asset value per share for the quarter that ended in Jun. 2023 was C$0.05.

The historical rank and industry rank for Origin Therapeutics Holdings's Net Current Asset Value or its related term are showing as below:

XCNQ:ORIG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.22 Med: 0.5 Max: 0.68
Current: 0.5

During the past 2 years, the highest Price-to-Net-Current-Asset-Value Ratio of Origin Therapeutics Holdings was 0.68. The lowest was 0.22. And the median was 0.50.

XCNQ:ORIG's Price-to-Net-Current-Asset-Value is not ranked
in the Drug Manufacturers industry.
Industry Median: 5.15 vs XCNQ:ORIG: 0.50

Origin Therapeutics Holdings Net Current Asset Value Historical Data

The historical data trend for Origin Therapeutics Holdings's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Origin Therapeutics Holdings Net Current Asset Value Chart

Origin Therapeutics Holdings Annual Data

Trend

Sep21

Sep22

Net Current Asset Value

0.09

Origin Therapeutics Holdings Quarterly Data
	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Net Current Asset Value	Get a 7-Day Free Trial				0.11	0.09	0.09	0.06	0.05

Competitive Comparison of Origin Therapeutics Holdings's Net Current Asset Value

For the Drug Manufacturers - Specialty & Generic subindustry, Origin Therapeutics Holdings's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Origin Therapeutics Holdings's Price-to-Net-Current-Asset-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Origin Therapeutics Holdings's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Origin Therapeutics Holdings's Price-to-Net-Current-Asset-Value falls into.

Origin Therapeutics Holdings Net Current Asset Value Calculation

Origin Therapeutics Holdings's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Sep. 2022 is calculated as

	Net Current Asset Value Per Share		(A: Sep. 2022 )
=	(Total Current Assets	-	Total Liabilities	-	Minority Interest	-	Preferred Stock)	/	Shares Outstanding (EOP)
=	(5.314	-	0.159	-	0	-	0)	/	56.563
=	0.09

Origin Therapeutics Holdings's Net Current Asset Value (NCAV) per share for the quarter that ended in Jun. 2023 is calculated as

	Net Current Asset Value Per Share		(Q: Jun. 2023 )
=	(Total Current Assets	-	Total Liabilities	-	Minority Interest	-	Preferred Stock)	/	Shares Outstanding (EOP)
=	(3.191	-	0.11	-	0	-	0)	/	56.563
=	0.05

Origin Therapeutics Holdings (XCNQ:ORIG) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.

Origin Therapeutics Holdings Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Origin Therapeutics Holdings's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.